|

JNJ-90301900 Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Functionalized hafnium oxide nanoparticles, NBTXR3

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Johnson & Johnson Enterprise Innovation Inc.2

Indications

  • Cancer2
  • Squamous Cell Carcinoma of Head and Neck1
  • Carcinoma, Non-Small-Cell Lung1
  • Lung Cancer1

Birmingham, Alabama1 trial

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Alabama at Birmingham

Phase 1

Farmington, Connecticut1 trial

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University of Connecticut Health Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.